PURPOSE: We investigated prognostic factors associated with survival in patients with non-small cell lung cancer (NSCLC) and oligometastatic disease at diagnosis, particularly the influence of local treatment to the primary site on prognosis. METHODS AND MATERIALS: From January 2000 through June 2011, 78 consecutive patients with oligometastatic NSCLC (<5 metastases) at diagnosis underwent definitive chemoradiation therapy (≥45 Gy) to the primary site. Forty-four of these patients also received definitive local treatment for the oligometastases. Survival outcomes were estimated using the Kaplan-Meier method, and risk factors were identified by univariate and multivariate analyses. RESULTS: Univariate Cox proportional hazard analysis revealed better overall survival (OS) for those patients who received at least 63 Gy of radiation to the primary site (P=.002), received definitive local treatment for oligometastasis (P=.041), had a Karnofsky performance status (KPS) score >80 (P=.007), had a gross tumor volume ≤124 cm³ (P=.002), had adenocarcinoma histology (P=.002), or had no history of respiratory disease (P=.016). On multivariate analysis, radiation dose, performance status, and tumor volume retained significance (P=.004, P=.006, and P<.001, respectively). The radiation dose also maintained significance when patients with and without brain metastases were analyzed separately. CONCLUSIONS: Tumor volume, KPS, and receipt of at least 63 Gy to the primary tumor are associated with improved OS in patients with oligometastatic NSCLC at diagnosis. Our results suggest that a subset of such patients may benefit from definitive local therapy.
PURPOSE: We investigated prognostic factors associated with survival in patients with non-small cell lung cancer (NSCLC) and oligometastatic disease at diagnosis, particularly the influence of local treatment to the primary site on prognosis. METHODS AND MATERIALS: From January 2000 through June 2011, 78 consecutive patients with oligometastatic NSCLC (<5 metastases) at diagnosis underwent definitive chemoradiation therapy (≥45 Gy) to the primary site. Forty-four of these patients also received definitive local treatment for the oligometastases. Survival outcomes were estimated using the Kaplan-Meier method, and risk factors were identified by univariate and multivariate analyses. RESULTS: Univariate Cox proportional hazard analysis revealed better overall survival (OS) for those patients who received at least 63 Gy of radiation to the primary site (P=.002), received definitive local treatment for oligometastasis (P=.041), had a Karnofsky performance status (KPS) score >80 (P=.007), had a gross tumor volume ≤124 cm³ (P=.002), had adenocarcinoma histology (P=.002), or had no history of respiratory disease (P=.016). On multivariate analysis, radiation dose, performance status, and tumor volume retained significance (P=.004, P=.006, and P<.001, respectively). The radiation dose also maintained significance when patients with and without brain metastases were analyzed separately. CONCLUSIONS:Tumor volume, KPS, and receipt of at least 63 Gy to the primary tumor are associated with improved OS in patients with oligometastatic NSCLC at diagnosis. Our results suggest that a subset of such patients may benefit from definitive local therapy.
Authors: Jose Luis Lopez Guerra; Qingyi Wei; Xianglin Yuan; Daniel Gomez; Zhensheng Liu; Yan Zhuang; Ming Yin; Minghuan Li; Li-E Wang; James D Cox; Zhongxing Liao Journal: Radiother Oncol Date: 2011-09-19 Impact factor: 6.280
Authors: Joline S W Lind; Frank J Lagerwaard; Egbert F Smit; Pieter E Postmus; Ben J Slotman; Suresh Senan Journal: Cancer Date: 2010-09-24 Impact factor: 6.860
Authors: Chaosu Hu; Eric L Chang; Samuel J Hassenbusch; Pamela K Allen; Shiao Y Woo; Anita Mahajan; Ritsuko Komaki; Zhongxing Liao Journal: Cancer Date: 2006-05-01 Impact factor: 6.860
Authors: Tommaso M De Pas; Filippo de Braud; Gianpiero Catalano; Carlo Putzu; Giulia Veronesi; Francesco Leo; Piero G Solli; Daniela Brambilla; Giovanni Paganelli; Lorenzo Spaggiari Journal: Ann Thorac Surg Date: 2007-01 Impact factor: 4.330
Authors: U Nestle; C Nieder; K Walter; U Abel; D Ukena; G W Sybrecht; K Schnabel Journal: Int J Radiat Oncol Biol Phys Date: 2000-08-01 Impact factor: 7.038
Authors: Todd W Flannery; Mohan Suntharalingam; William F Regine; Lawrence S Chin; Mark J Krasna; Michael K Shehata; Martin J Edelman; Marnie Kremer; Roy A Patchell; Young Kwok Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-14 Impact factor: 7.038
Authors: Maria Werner-Wasik; R Suzanne Swann; Jeffrey Bradley; Mary Graham; Bahman Emami; James Purdy; William Sause Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-14 Impact factor: 7.038
Authors: K Mohnike; K Neumann; P Hass; M Seidensticker; R Seidensticker; M Pech; S Klose; T Streitparth; B Garlipp; C Benckert; J J Wendler; U B Liehr; M Schostak; D Göppner; G Gademann; J Ricke Journal: Strahlenther Onkol Date: 2017-03-24 Impact factor: 3.621
Authors: Garrett Jensen; Chad Tang; Kenneth R Hess; Andrew J Bishop; Hubert Y Pan; Jing Li; James N Yang; Nizar M Tannir; Behrang Amini; Claudio Tatsui; Laurence Rhines; Paul D Brown; Amol J Ghia Journal: J Radiosurg SBRT Date: 2017
Authors: Jill F Mentink; Marthe S Paats; Daphne W Dumoulin; Robin Cornelissen; Joris B W Elbers; Alexander P W M Maat; Jan H von der Thüsen; Anne-Marie C Dingemans Journal: Transl Lung Cancer Res Date: 2021-07